UBS AM
AKBA icon

UBS AM’s Akebia Therapeutics AKBA Stock Holding History

UBS AM’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-319,797
Closed -$515K – 3808
2025
Q4 		$515K Sell
319,797
-7,162
-2% -$15K ﹤0.01% 2313
2025
Q3 		$893K Buy
326,959
+299,654
+1,097% +$997K ﹤0.01% 2043
2025
Q2 		$99.4K Buy
+27,305
New +$75K ﹤0.01% 2589
2022
Q2 		– Sell
-180,790
Closed -$130K – 2689
2022
Q1 		$130K Hold
180,790
– – ﹤0.01% 2719
2021
Q4 		$409K Buy
180,790
+6,617
+4% +$18K ﹤0.01% 2619
2021
Q3 		$502K Sell
174,173
-24,567
-12% -$70.1K ﹤0.01% 2500
2021
Q2 		$753K Buy
198,740
+105,322
+113% +$355K ﹤0.01% 2357
2021
Q1 		$316K Buy
93,418
+5,338
+6% +$19.2K ﹤0.01% 2478
2020
Q4 		$247K Hold
88,080
– – ﹤0.01% 2457
2020
Q3 		$221K Sell
88,080
-1,107
-1% -$9.71K ﹤0.01% 2380
2020
Q2 		$1.21M Buy
89,187
+10,058
+13% +$104K ﹤0.01% 1719
2020
Q1 		$600K Sell
79,129
-4,350
-5% -$33.8K ﹤0.01% 1905
2019
Q4 		$528K Buy
83,479
+3,170
+4% +$15.1K ﹤0.01% 2215
2019
Q3 		$315K Buy
80,309
+5,478
+7% +$23.5K ﹤0.01% 2440
2019
Q2 		$362K Buy
74,831
+11,313
+18% +$64.4K ﹤0.01% 2343
2019
Q1 		$520K Buy
63,518
+22,806
+56% +$157K ﹤0.01% 2094
2018
Q4 		$225K Buy
40,712
+22,912
+129% +$179K ﹤0.01% 2340
2018
Q3 		$157K Hold
17,800
– – ﹤0.01% 2491
2018
Q2 		$178K Hold
17,800
– – ﹤0.01% 2498
2018
Q1 		$170K Buy
+17,800
New +$249K ﹤0.01% 2410

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS AM's AKBA Position: Q1 2026 in Review

UBS AM sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 319,797 shares — an estimated $515K sold.

UBS AM first reported a position in AKBA in Q1 2018 and held it in 20 quarters. The position peaked at $1.21M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • UBS AM reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • UBS AM sold 319,797 Akebia Therapeutics shares in Q1 2026, an estimated $515K.
  • UBS AM first reported a position in Akebia Therapeutics in Q1 2018 and held it in 20 quarters.
  • UBS AM's Akebia Therapeutics position peaked at $1.21M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.